ASX RELEASE 29 March 2021 Kazia licenses paxalisib to Simcere in Greater China
Simcere will assume responsibility for the development, registration, and commercialisation of paxalisib in Greater China - a territory which includes Mainland China, Hong Kong, Macau, and Taiwan.
Under the terms of the agreement, Kazia will receive an upfront payment of US$ 11 million (~AU$ 14.2 million), comprising US$ 7 million in cash and a US$ 4 million equity investment, priced at a 20% premium to recent trading. Kazia will also receive contingent milestone payments of up to US$ 281 million (at present AU$ 388 million) for glioblastoma, with further milestones payable for indications beyond glioblastoma. Simcere will additionally pay to Kazia mid-teen percentage royalties on commercial sales.
.................................................................................................... ASX RELEASE 21 April 2022 PHASE II STUDY OF PAXALISIB IN GLIOBLASTOMA ACHIEVES FINAL COMPLETION; DATA TO BE PRESENTED AT UPCOMING CONFERENCE
Next Steps The GBM AGILE pivotal study in glioblastoma commenced recruitment to the paxalisib arm in January 2021. At present, recruitment to the paxalisib arm is ongoing in the United States and Canada, and the study is expected to open in Europe and China during Q2 or Q3 of CY2022. Final data from the study is expected in 2H CY2023.
IMO expect Simcere contingent milestone payments of up to US$ 281 million (at present AU$ 388 million) for glioblastoma, based on progress in China of the GBM AGILE study arm of paxalisib. A final payment based on Simcere receiving a paxalisib drug marketing approval for glioblastoma treatment from the Chinese regulators.
Is there more regional paxalisib licences for glioblastoma to be announced during CY 2022?
Regards.
KZA Price at posting:
$1.09 Sentiment: Buy Disclosure: Held
